Ab38007

IHC was performed as previously described^{14 (link)}. Anti-NFAT5 (1:100, Abcam, ab226308), PGK1 (1:100, Abcam, ab38007), and anti-PCNA (1:500, Cell Signaling Technology, #13110) antibodies were used. Tumor tissues were scored according to the percentage of stained area (0 = 0%, 1 = 1–10%, 2 = 11–50%, 3 = 51–80%, and 4 = 81–100%) and darkness of the nuclei or cytoplasm staining (0 = no staining, 1 = weak staining, 2 = moderate staining, and 3 = strong staining). Final scores were determined by multiplying the 2 numbers mentioned above (“negative” for a score of 0, “weak” for a score of 1–4, “moderate” for a score of 5–8, and “positive” for a score of 9–12). The high-expression group had scores greater than 5, while the low-expression group scores were ≤5.

A Cell Counting Kit-8 (CCK-8, Cat# CK04) was purchased from Dojindo (Kumamoto, Japan). Pooled antisense oligonucleotides (i.e., siRNAs) against human OVOL2, P65, and GLUT1 were purchased from GenePharma (Shanghai, China). Antibodies against OVOL2 (Cat# ab101580) and P65 (Cat# ab16502) were purchased from Abcam (Cambridge, MA, USA). The following antibodies were used: Glycolysis Antibody Sampler Kits (Cell Signaling Technology; Cat# 12866 and Cat# 8337), anti-GLUT1, anti-GLUT2, anti-GLUT3, anti-GLUT4, anti-PGK1, anti-GCK, anti-PDP2, anti-DLD, anti-PCK1, anti-SDHA, anti-G6PD (all from Abcam; Cat# ab115730, ab234440, ab191071, ab188317, ab38007, ab184169, ab99170, ab133551, ab28455, ab14715, and ab210702, respectively), anti-GAPDH anti-Lamin B, anti-actin and anti-Calnexin (all from Cell Signaling Technology; Cat# 8884, 13435, 3700 and 2433, respectively).